Compare Stocks: HURA, CBIO, CAPR, and YDES

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CAPR Capricor Therapeutics	$8.95 +0.1%	$7.53	$2.96 ▼ $40.37	$520.34M	0.61	3.46 million shs	2.55 million shs
CBIO Crescent Biopharma	$14.32 +0.4%	$16.92	$8.72 ▼ $27.41	$531.90M	1.27	516,818 shs	283,270 shs
HURA TuHURA Biosciences	$1.91 -3.5%	$2.12	$0.41 ▼ $3.43	$121.72M	-0.21	209,659 shs	287,680 shs
YDES YD Bio	$8.11 +3.8%	$3.86	$1.70 ▼ $22.00	$574.10M	-1.55	646,729 shs	546,512 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CAPR Capricor Therapeutics	0.00%	+7.06%	-3.56%	-61.44%	+14.45%
CBIO Crescent Biopharma	0.00%	+2.36%	-29.80%	-16.21%	+20.34%
HURA TuHURA Biosciences	0.00%	-9.05%	-9.05%	-21.72%	-24.80%
YDES YD Bio	0.00%	+41.54%	+120.98%	+326.84%	+810,999,900.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CAPR Capricor Therapeutics	$8.95 +0.1%	$7.53	$2.96 ▼ $40.37	$520.34M	0.61	3.46 million shs	2.55 million shs
CBIO Crescent Biopharma	$14.32 +0.4%	$16.92	$8.72 ▼ $27.41	$531.90M	1.27	516,818 shs	283,270 shs
HURA TuHURA Biosciences	$1.91 -3.5%	$2.12	$0.41 ▼ $3.43	$121.72M	-0.21	209,659 shs	287,680 shs
YDES YD Bio	$8.11 +3.8%	$3.86	$1.70 ▼ $22.00	$574.10M	-1.55	646,729 shs	546,512 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CAPR Capricor Therapeutics	0.00%	+7.06%	-3.56%	-61.44%	+14.45%
CBIO Crescent Biopharma	0.00%	+2.36%	-29.80%	-16.21%	+20.34%
HURA TuHURA Biosciences	0.00%	-9.05%	-9.05%	-21.72%	-24.80%
YDES YD Bio	0.00%	+41.54%	+120.98%	+326.84%	+810,999,900.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CAPR Capricor Therapeutics	2.27	Hold	$30.25	237.99% Upside
CBIO Crescent Biopharma	2.83	Moderate Buy	$29.60	106.70% Upside
HURA TuHURA Biosciences	2.67	Moderate Buy	$9.00	371.20% Upside
YDES YD Bio	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest HURA, CBIO, CAPR, and YDES Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/17/2026	CAPR Capricor Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
9/14/2026	CAPR Capricor Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$5.00 ➝ $21.00
9/14/2026	CAPR Capricor Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$5.00 ➝ $21.00
9/14/2026	CBIO Crescent Biopharma	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$27.00
9/11/2026	CAPR Capricor Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/1/2026	CAPR Capricor Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Overweight
8/27/2026	CBIO Crescent Biopharma	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$27.00
8/25/2026	CAPR Capricor Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform
8/24/2026	CBIO Crescent Biopharma	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/18/2026	HURA TuHURA Biosciences	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$9.00
8/14/2026	CAPR Capricor Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Overweight

(Data available from 10/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CAPR Capricor Therapeutics	$22.27M	23.37	N/A	N/A	$5.53 per share	1.62
CBIO Crescent Biopharma	$10.84M	49.06	N/A	N/A	$14.32 per share	1.00
HURA TuHURA Biosciences	N/A	N/A	N/A	N/A	$0.34 per share	N/A
YDES YD Bio	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CAPR Capricor Therapeutics	-$105.04M	-$2.45	N/A	N/A	N/A	N/A	-56.60%	-43.97%	11/9/2026 (Estimated)
CBIO Crescent Biopharma	-$153.94M	-$6.72	N/A	N/A	N/A	N/A	-101.50%	-86.86%	11/5/2026 (Estimated)
HURA TuHURA Biosciences	-$30.05M	-$0.54	N/A	N/A	N/A	N/A	-156.47%	-106.98%	11/13/2026 (Estimated)
YDES YD Bio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest HURA, CBIO, CAPR, and YDES Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/1/2026	Q2 2026	YDES YD Bio	N/A	$0.05	N/A	$0.0450	N/A	$0.42 million
8/14/2026	Q2 2026	HURA TuHURA Biosciences	-$0.1533	-$0.14	+$0.0133	-$0.14	N/A	N/A
8/13/2026	Q2 2026	CAPR Capricor Therapeutics	-$0.5889	-$0.70	-$0.1111	-$0.70	$2.08 million	N/A
7/30/2026	Q2 2026	CBIO Crescent Biopharma	-$0.7357	-$0.74	-$0.0043	-$0.74	$0.36 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CAPR Capricor Therapeutics	N/A	N/A	N/A	N/A	N/A
CBIO Crescent Biopharma	N/A	N/A	N/A	N/A	N/A
HURA TuHURA Biosciences	N/A	N/A	N/A	N/A	N/A
YDES YD Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CAPR Capricor Therapeutics	N/A	7.35	7.35
CBIO Crescent Biopharma	N/A	9.66	9.66
HURA TuHURA Biosciences	0.20	0.18	0.18
YDES YD Bio	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CAPR Capricor Therapeutics	21.68%
CBIO Crescent Biopharma	75.19%
HURA TuHURA Biosciences	0.62%
YDES YD Bio	N/A

Insider Ownership

Company	Insider Ownership
CAPR Capricor Therapeutics	9.20%
CBIO Crescent Biopharma	24.84%
HURA TuHURA Biosciences	6.06%
YDES YD Bio	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CAPR Capricor Therapeutics	231	58.14 million	52.79 million	Optionable
CBIO Crescent Biopharma	44	37.14 million	27.92 million	No Data
HURA TuHURA Biosciences	22	63.73 million	59.87 million	N/A
YDES YD Bio	15	70.79 million	N/A	N/A

HURA, CBIO, CAPR, and YDES Headlines

Recent News About These Companies

Wall Street Zen Upgrades YD Bio (NASDAQ:YDES) to "Hold"

September 26, 2026 | americanbankingnews.com

Cours YD Bio Limited

September 24, 2026 | zonebourse.comZ

YD Bio (NASDAQ:YDES) CEO Ethan Phd Shen Purchases 3,100 Shares of Stock

September 11, 2026 | insidertrades.com

中概股跌幅榜前十，YD Bio Limited(YDES.US)跌22.71%，房多多(DUO.US)跌20.85%

September 1, 2026 | finet.hkF

YD Bio Ltd (YDES)

September 1, 2026 | finance.yahoo.com

YD Bio Files First-Half 2026 Results, Reports Improved Equity Position

September 1, 2026 | tipranks.com

YD Bio Limited Reports First-Half 2026 Financial Results, 315% Revenue Growth and Net Income of $6.7 Million

August 31, 2026 | quiverquant.comQ

YD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026

August 31, 2026 | globenewswire.com

YDES - YD Bio Limited

August 26, 2026 | seekingalpha.com

Yd Bio Limited publie un article de revue évalué par les pairs dans Nutrients et lance deux produits nutraceutiques à Taïwan

August 26, 2026 | zonebourse.comZ

YD Bio Announces Peer-Reviewed Publication in Nutrients, Co-Authored with Physicians from the Taiwan Chronic Disease Healthcare Association and the Future Health Institute

August 25, 2026 | globenewswire.com

YD Bio Launches a Physician-Partnership Initiative in Taiwan with the Announcement of Two Nutraceutical Products in Collaboration with the Taiwan Chronic Disease Healthcare ...

August 11, 2026 | markets.businessinsider.com

YD Bio Launches Physician-Led Nutraceuticals in Taiwan to Build Consumer Health Ecosystem

August 11, 2026 | tipranks.com

YD Bio Highlights Peer-Reviewed Publication on New Computational Framework for Keratoconus Research

August 4, 2026 | markets.businessinsider.com

YD Bio Launches Cross-Border Cancer Testing Pilot with Numia Health to Evaluate Expanded Access to Molecular Diagnostics in Canada

July 28, 2026 | finance.yahoo.com

YD Bio and EG BioMed Conclude Successful Exhibition at BIO Asia-Taiwan 2026, Highlighting Innovations in Ophthalmology, Oncology Diagnostics, and Clinical Services

July 24, 2026 | markets.businessinsider.com

YD Bio Limited

July 15, 2026 | cnn.com

YD Bio Limited Ordinary Shares (YDES) Insider Activity

July 14, 2026 | nasdaq.com

YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations

July 2, 2026 | globenewswire.com

YD Bio Ltd.

June 25, 2026 | barrons.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

HURA, CBIO, CAPR, and YDES Company Descriptions

Capricor Therapeutics NASDAQ:CAPR

$8.95 +0.01 (+0.11%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$9.02 +0.07 (+0.74%)

As of 10/2/2026 07:59 PM Eastern

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

Crescent Biopharma NASDAQ:CBIO

$14.32 +0.06 (+0.42%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$14.15 -0.17 (-1.17%)

As of 10/2/2026 07:57 PM Eastern

Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.

TuHURA Biosciences NASDAQ:HURA

$1.91 -0.07 (-3.54%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$1.95 +0.04 (+2.09%)

As of 10/2/2026 07:30 PM Eastern

TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.

YD Bio NASDAQ:YDES

$8.11 +0.30 (+3.84%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$7.99 -0.12 (-1.47%)

As of 10/2/2026 07:57 PM Eastern

YD Bio Limited is a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HURA, CBIO, CAPR, and YDES Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HURA, CBIO, CAPR, and YDES Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HURA, CBIO, CAPR, and YDES Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

HURA, CBIO, CAPR, and YDES Company Descriptions

Capricor Therapeutics NASDAQ:CAPR

Crescent Biopharma NASDAQ:CBIO

TuHURA Biosciences NASDAQ:HURA

YD Bio NASDAQ:YDES

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HURA, CBIO, CAPR, and YDES Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HURA, CBIO, CAPR, and YDES Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HURA, CBIO, CAPR, and YDES Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

HURA, CBIO, CAPR, and YDES Company Descriptions

Capricor Therapeutics NASDAQ:CAPR

Crescent Biopharma NASDAQ:CBIO

TuHURA Biosciences NASDAQ:HURA

YD Bio NASDAQ:YDES

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools